| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). |
| Assessment Process | |
| Rapid review commissioned | 29/03/2019 |
| Rapid review completed | 29/04/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/05/2019 |
| Pre-submission consultation with Applicant | 10/06/2019 |
| Full submission received from Applicant | 30/08/2019 |
| Preliminary review sent to Applicant | 20/12/2019 |
| NCPE assessment re-commenced | 30/01/2020 |
| Factual accuracy sent to Applicant | 16/04/2020 |
| NCPE assessment re-commenced | 24/04/2020 |
| NCPE assessment completed | 07/05/2020 |
| NCPE assessment outcome | The NCPE recommends that durvalumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations February 2021.
